Literature DB >> 16707511

Measurement of quality of life in pulmonary hypertension and its significance.

E Cenedese1, R Speich, L Dorschner, S Ulrich, M Maggiorini, R Jenni, M Fischler.   

Abstract

Until recently, assessment of patients with pulmonary hypertension has mainly relied on functional and haemodynamic parameters. Health-related quality of life (HRQOL), however, has become increasingly important in defining overall health status. The present study investigated the performance and clinical relevance of the Minnesota Living with Heart Failure (MLHF) questionnaire by prospectively studying 48 patients with either pulmonary arterial hypertension (n = 26) or chronic thromboembolic pulmonary hypertension (n = 22). The MLHF scores were correlated to various clinical and haemodynamic parameters. Prognostic outcome was evaluated by calculating the time taken to reach an adverse clinical event defined as death, lung transplantation or pulmonary endarterectomy. The reliability of test-re-test and internal consistency of this HRQOL tool was high. The MLHF score and its physical subscore correlated moderately to well with functional and haemodynamic parameters, except in the case of pulmonary artery pressures. Both scores significantly improved during vasodilator therapy. This figure was surpassed only by the New York Heart Association/World Health Organization functional class. A multivariate analysis of all variables revealed that the MLHF score was the sole factor predicting subsequent outcome. The Minnesota Living with Heart Failure questionnaire is highly reproducible, consistent, and a moderately valid and responsive tool in assessing health-related quality of life in pulmonary hypertension. Moreover, it is a significant predictor of outcome in these patients.

Entities:  

Mesh:

Year:  2006        PMID: 16707511     DOI: 10.1183/09031936.06.00130405

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  36 in total

1.  Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension.

Authors:  H Chen; T De Marco; E A Kobashigawa; P P Katz; V W Chang; P D Blanc
Journal:  Eur Respir J       Date:  2011-01-27       Impact factor: 16.671

Review 2.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

Review 3.  Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension.

Authors:  Hubert Chen; Darren B Taichman; Ramona L Doyle
Journal:  Proc Am Thorac Soc       Date:  2008-07-15

4.  Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  Colm McCabe; Maxine Bennett; Natalie Doughty; Robert MacKenzie Ross; Linda Sharples; Joanna Pepke-Zaba
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

5.  Physician attitudes toward palliative care for patients with pulmonary arterial hypertension: results of a cross-sectional survey.

Authors:  Eric R Fenstad; Tait D Shanafelt; Jeff A Sloan; Paul J Novotny; Louise A Durst; Robert P Frantz; Michael D McGoon; Keith M Swetz
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

6.  Prostacyclin for pulmonary arterial hypertension.

Authors:  Hayley Barnes; Hui-Ling Yeoh; Toby Fothergill; Andrew Burns; Marc Humbert; Trevor Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-05-01

Review 7.  Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

8.  The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension.

Authors:  Rubina M Khair; Chisom Nwaneri; Rachel L Damico; Todd Kolb; Paul M Hassoun; Stephen C Mathai
Journal:  Ann Am Thorac Soc       Date:  2016-06

9.  Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism.

Authors:  M G J Duffels; M N van der Plas; S Surie; M M Winter; B Bouma; M Groenink; A P J van Dijk; E Hoendermis; R M F Berger; P Bresser; B J M Mulder
Journal:  Neth Heart J       Date:  2009-09       Impact factor: 2.380

10.  Exercise capacity affects quality of life in patients with pulmonary hypertension.

Authors:  Michael Halank; Franziska Einsle; Stephanie Lehman; Hinrich Bremer; Ralf Ewert; Heinrike Wilkens; F Joachim Meyer; Ekkehard Grünig; Hans-Jürgen Seyfarth; Martin Kolditz; Gesine Wieder; Gert Höffken; Volker Köllner
Journal:  Lung       Date:  2013-05-17       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.